Renalytix PLC
08 September 2026
Renalytix plc
("RenalytixTM" or the "Company")
Posting of Circular
and
Notice of General Meeting
LONDON and NEW YORK, 8 September, 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, confirms that, further to the Company's announcement released at 07:01 on 1 September 2026 (RNS Number: 8254S), a shareholder circular, containing the Notice of the General Meeting setting out the Resolutions and further details on the Fundraising, has been posted to Shareholders and is available on the Company's website at https://investors.renalytix.com/documents/.
The General Meeting to approve the Resolutions will be held at 12.00 p.m. on 28 September 2026 at 1 Bow Churchyard, London EC4M 9DQ.
The Circular includes a recommendation from Directors that all Shareholders of the Company vote in favour of the Resolutions, as they intend to do in respect of their own holdings of Ordinary Shares representing 5.5 per cent. of the current issued share capital of the Company.
For further information, please contact:
|
Renalytix plc |
||
|
James McCullough, CEO |
Via Walbrook PR |
|
|
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
David Hignell / Jen Clarke (Corporate Finance) |
||
|
Vadim Alexandre (Corporate Broking) |
||
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Nick Lovering |
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
LEI - 213800NTOH3FK3WER551
About kidneyintelX.dkd and Renalytix (www.kidneyintelx.com and www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. It's KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States' and the United Kingdom's medical systems, affecting approximately 15 million and 8 million people, respectively.
Renalytix has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.